Selective product in-licensing or acquisition will enable Vallon Pharmaceuticals to rapidly build a diversified pipeline of drugs to treat CNS disorders.
SOURCE. Academia, startup, or pharma
STAGE. Preclinical development through Phase 2-ready
TYPE. Small molecule – NCE or reformulation with novel IP
Vallon has developed ADAIR in collaboration with Lonza’s formulation development team in Edinburgh, Scotland